Rosuvasatin sprinkle capsules can are designed to be opened and the extended release coated pellets may be sprinkled over soft food, taken whole or via a nasogastric tube.
We have added two new products to the database today, Posaconazole & Cannabidiol. If there are product that you would like us to investigate and add to our database, please email us on email@example.com
Information on Dasatinib has been added to the database.
We have been working very hard to update the database and add more useful information and additional formulations. we hope that you find this additional information useful. Let us know if there is more information that you would like to see on the website.
A new oral liquid zonisamide has recently been launched in the UK and this information has been added to the product page.
Rivaroxaban (Xarelto) has been added to the database
Afatinib and Albendazole
New monographs available for:
Afatinib – licensed for administration via gastric tubes. The medication can also be dissolved in water to aid patients with swallowing difficulties. See the monograph for full information.
Albendazole- unlicensed medication available as an imported special on a named patient basis. Limited information available. See the monograph for full information.
Glenmark Pharma have two new branded generic soluble products. Glensoludex is a soluble dexamethasone tablet, available in strengths of 2mg, 4mg and 8mg. Glensoludex is indicated for use in certain endocrine and non-endocrine disorders, in certain cases of cerebral oedema and for diagnostic testing of adrenocortical hyperfunction.
Alzhok is a soluble memantine tablet, available in strengths of 5mg, 10mg, 15mg, 20mg. Alzhok is indicated for the treatment of adult patients with moderate to severe Alzheimer’s disease.
In Jan 2017 the UK Patient’s Association launched a charter to improve the care of residents in care homes who have swallowing difficulties. In response to a survey results which identified sub-optimal practices with respect to covert administration and medicines administration for care home residents with dysphagia, the Patient’s Association convened an advisory group to address the problem. Consisting of representatives from care homes, primary care organisations, the nursing, medical and pharmacy professions and leading academics in the field, nine point charters for both patients and healthcare professionals were developed. With recommendations that medicines and formulation choice be regularly reviewed, that residents are placed at the centre of any decision making and assessment for dysphagia is regularly undertaken it is hoped that residents in care homes will receive better quality care. Detailed guidance on the charter and how to implement it into care homes is due in August.